A blood test that screens for more than 50 types of cancer from a single draw is no longer something Canadians can only read about in American headlines. Since the fall of 2025, the Galleri test, developed by California-based GRAIL, has been quietly offered at a handful of private clinics in the Toronto area. The price tag: about $2,099, paid entirely out of pocket. No provincial health plan covers it, Health Canada has not approved it, and no Canadian medical society recommends it. Yet demand is real, and at least one major insurer has started to subsidize it. Here is what the test can do, what it cannot, and what Canadian doctors want patients to understand before they book an appointment.
What the Galleri test actually measures
Galleri belongs to a new class of screening tools called multi-cancer early detection (MCED) tests. When tumour cells die, they shed fragments of DNA into the bloodstream. The test sequences this cell-free DNA and reads its methylation patterns, chemical tags that differ depending on the tissue the DNA came from and whether it came from cancerous cells.
From one blood sample, the test answers two questions: is there a cancer signal present, and if so, where in the body is it most likely coming from? In published studies, the predicted cancer signal origin matched the eventual diagnosis roughly 93 percent of the time when a signal was found, which helps physicians decide which follow-up scans to order. The underlying science builds on the same wave of molecular medicine that has produced advances in nanoparticle-based cancer therapies over the past decade.
Where Canadians can get it
Galleri arrived in Canada in October 2025 through a small number of private executive-health providers. Access, for now, is concentrated in southern Ontario.
| Provider | Location | Approximate cost | Notes |
|---|---|---|---|
| Medcan | Toronto and Oakville, ON | ~$2,099 | First Canadian provider; physician review before and after testing |
| Wellness Haus | Toronto, ON | ~$2,099 | Offered within private longevity and diagnostics programs |
| Manulife (insurance route) | Canada-wide | Subsidized for eligible members | Vitality Plus members aged 50 and over; first Canadian insurer to cover an MCED test |
Manulife’s move is worth noting: it marked the first time a Canadian insurer put money behind a multi-cancer blood test, a signal that the private market expects these tests to become mainstream even while regulators stay silent.
Why no provincial plan pays for it
The short answer is that Galleri is not an approved medical device in Canada. It is sold as a laboratory-developed test, a category that lets a certified lab offer its own test without the device-approval process that Health Canada, or the FDA in the United States, would normally require. Neither agency has approved Galleri, and no major oncology society, including the American Society of Clinical Oncology, currently endorses multi-cancer screening for the general population.
Provincial health systems fund cancer screening only where trials have shown that screening saves lives: mammography for breast cancer, Pap and HPV testing for cervical cancer, FIT testing and colonoscopy for colorectal cancer, and low-dose CT for high-risk smokers. Galleri has not yet cleared that bar. A randomized trial run with the National Health Service in the UK, involving about 140,000 participants, is the study most experts are waiting on before any public system commits.
The numbers behind the marketing
The test’s headline strength is specificity: about 99.5 percent, meaning false alarms are rare across the whole tested population. But the number patients should scrutinize is the positive predictive value. In the PATHFINDER study, which followed more than 6,000 American adults, only about 38 percent of people who received a positive cancer signal actually turned out to have cancer. The other 62 percent went through weeks of scans, biopsies and anxiety before getting the all-clear. The reassuring flip side: a negative result was correct about 99 percent of the time.
Sensitivity also varies enormously by cancer type. Published data show the test catches roughly 84 percent of pancreatic cancers and 85 percent of esophageal cancers, tumour types that shed abundant DNA and for which no routine screening exists. For prostate cancer, sensitivity drops to around 11 percent. The test also performs poorly for brain tumours, skin cancers and many stage 1 cancers, precisely the early stage a screening test is supposed to catch.
What doctors tell their patients
Canadian physicians who offer the test frame it the same way GRAIL does: an addition to routine screening, never a replacement. A negative Galleri result does not mean a patient can skip a scheduled mammogram or colonoscopy. Doctors also warn about the downstream costs of a positive signal, since follow-up PET scans or biopsies may not always be quickly accessible in a public system already managing long imaging wait times.
There is also a selection question. The people most likely to spend $2,099 on peace of mind, affluent, health-conscious adults, are not necessarily the people at highest cancer risk. Researchers in molecular diagnostics, including teams working on nanoscale tools for detecting disease, point out that the technology is advancing faster than the evidence that using it actually extends lives.
FAQ: Galleri in Canada
Is the Galleri test covered by OHIP, RAMQ or other provincial plans?
No. As of 2026, no provincial or territorial health plan covers Galleri or any other multi-cancer early detection test. The roughly $2,099 cost is paid out of pocket, unless you qualify through a private insurance program such as Manulife Vitality Plus.
Can my family doctor order the test?
Not through the public system. The test is currently available through private clinics such as Medcan and Wellness Haus, which include their own physician consultation to review results and arrange follow-up if a signal is detected.
How accurate is the Galleri test?
Very few false alarms (99.5 percent specificity), but among people who do get a positive signal, only about 38 percent are found to have cancer. Detection rates range from over 80 percent for some aggressive cancers to about 11 percent for prostate cancer, and the test is significantly less reliable for early-stage tumours.
Should I keep doing regular cancer screening if I take the test?
Yes, without exception. Galleri is designed to complement, not replace, mammograms, colonoscopies, Pap tests and lung CT screening, which remain the only screening methods proven to reduce cancer deaths and the only ones covered by provincial plans.
This article is for information purposes only and is not medical advice. Speak with a physician before making any decision about cancer screening.
